Cargando…

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings

INTRODUCTION: The aim of this study was to understand the reasons for canakinumab initiation among patients with Still’s disease, including systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD), in US clinical practice. METHODS: Physicians retrospectively reviewed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hur, Peter, Yi, Esther, Ionescu-Ittu, Raluca, Manceur, Ameur M., Lomax, Kathleen G., Cammarota, Jordan, Xie, Jipan, Gautam, Raju, Nakasato, Priscila, Sanghera, Navneet, Kim, Nina, Grom, Alexei A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814295/ https://www.ncbi.nlm.nih.gov/pubmed/34874547 http://dx.doi.org/10.1007/s40744-021-00402-z

Ejemplares similares

Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States
por: Hur, Peter, et al.
Publicado: (2021)

Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
por: Dunger-Baldauf, Cornelia, et al.
Publicado: (2022)

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
por: Mehta, Sandhya, et al.
Publicado: (2023)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive
por: Ghate, Sameer, et al.
Publicado: (2019)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
por: Vitale, Antonio, et al.
Publicado: (2020)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et al
por: Brunner, Hermine, et al.
Publicado: (2015)

Canakinumab and mycophenolate mofetil in managing proteinuria/renal amyloidosis secondary to adult-onset Still’s disease
por: Feng, Jin, et al.
Publicado: (2023)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

The Reason is Still Unclear
por: Ogura, Masatsune
Publicado: (2022)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada
por: Ionescu-Ittu, Raluca, et al.
Publicado: (2009)

The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data
por: Sulkowski, Mark, et al.
Publicado: (2020)

Differential monocyte microrna expression profiles in children with active systemic juvenile idiopathic arthritis
por: Schulert, Grant, et al.
Publicado: (2014)

Impact of systemic juvenile idiopathic arthritis/Still’s disease on adolescents as evidenced through social media posts
por: Modica, Renee F, et al.
Publicado: (2018)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Uncertainty of Monetary Valued Ecosystem Services – Value Transfer Functions for Global Mapping
por: Schmidt, Stefan, et al.
Publicado: (2016)

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
por: Sunkureddi, Prashanth, et al.
Publicado: (2019)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Canakinumab for refractory RA: a case report
por: Marketos, Nikolaos, et al.
Publicado: (2018)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

Some Reasons Why Lithotomy Is Still Performed
por: Birdwood, G. T.
Publicado: (1900)

Single-Heuristic Reasoning: Is It Still Dual-Process?
por: Valerjev, Pavle, et al.
Publicado: (2023)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8civga63u8gsi3jsndl4dvu93q